The Role of Resistance Training in Non Alcoholic Fatty Liver Disease
1 other identifier
interventional
82
1 country
1
Brief Summary
The aim of the study is to evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2010
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 6, 2010
CompletedStudy Start
First participant enrolled
December 1, 2010
CompletedFirst Posted
Study publicly available on registry
December 21, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2012
CompletedMarch 27, 2014
December 1, 2010
1.8 years
July 6, 2010
March 26, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
The HRI value will be reduced in the intervention arm as compared to the The The change in Hepato-Renal Index (HRI) evaluated by ultrasound (US).
week 0 and week 13
Study Arms (2)
Stretching Exercises
SHAM COMPARATORThe patients will perform twice weekly home based static stretching workout.
Resistance Training
EXPERIMENTALThe patients will perform twice weekly supervised RT for 3 months
Interventions
Eligibility Criteria
You may qualify if:
- Ultrasound diagnosed fatty liver.
You may not qualify if:
- Presence of HBsAg or anti-HCV antibodies (will be obtained from blood tests at the liver clinic).
- Patients with known diabetes treated with antidiabetic medications.
- Patients with known kidney disease, CHD, lung disease, inflammatory bowel disease.
- Excessive alcohol consumption ≥ 30 g/day in men or 20 g/ day in women.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tel Aviv Sourasky Medical center
Tel Aviv, 64239, Israel
Related Publications (1)
Zelber-Sagi S, Azar S, Nemirovski A, Webb M, Halpern Z, Shibolet O, Tam J. Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. Obesity (Silver Spring). 2017 Jan;25(1):94-101. doi: 10.1002/oby.21687. Epub 2016 Nov 15.
PMID: 27863097DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ran Oren, MD
Tel-Aviv Sourasky Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
July 6, 2010
First Posted
December 21, 2010
Study Start
December 1, 2010
Primary Completion
September 1, 2012
Study Completion
October 1, 2012
Last Updated
March 27, 2014
Record last verified: 2010-12